

**REMARKS**

The specification has been amended to recite a deposit accession number for the VTm1.1 antibody. Claim 7 has been amended to refer to the deposit accession number. Claim 13 has been amended to delete reference to VTm1.1. Claim 5 has been amended to delete the word "specific" in response to the Examiner's comments discussed further below. No amendment should be construed as acquiescence in any ground of rejection.

Applicants now address the Examiner's remarks using the paragraph numbering of the office action.

3. The VTm1.1 antibody has now been deposited, so the rejection is moot.

13. The designation VTm1.1 has been deleted from claims 7 and 13. In claim 7, the mouse antibody is defined by deposit number. In claim 13, further definition is not needed because the mouse antibody is defined by sequence in antecedent claim 5.

14. The rejection is moot in view of deposit of the VTm1.1 antibody.


15-16. Claim 5 stands rejected on the basis that applicants have not enabled an antibody that specifically binds to VT2 without binding to VT1. In reply, applicants did not intend the language specifically binds to mean that the antibody binds to VT2 to the exclusion of VT1. Nevertheless, the claim has been amended to delete "specifically."

Appl. No. 09/700,851  
Amdt. dated September 26, 2007  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1645

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Joe Liebeschuetz  
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 415-576-0300  
Attachments  
JOL:sjj  
61142031 v1